These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 23892411)

  • 21. UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.
    Schulz C; Heinemann V; Schalhorn A; Moosmann N; Zwingers T; Boeck S; Giessen C; Stemmler HJ
    World J Gastroenterol; 2009 Oct; 15(40):5058-66. PubMed ID: 19859999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
    Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
    Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
    [No Abstract]   [Full Text] [Related]  

  • 23. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.
    Marcuello E; Páez D; Paré L; Salazar J; Sebio A; del Rio E; Baiget M
    Br J Cancer; 2011 Jun; 105(1):53-7. PubMed ID: 21654688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.
    Sugiyama T; Hirose T; Kusumoto S; Shirai T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
    Oncol Res; 2010; 18(7):337-42. PubMed ID: 20377135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
    Kudoh S; Fukuoka M; Masuda N; Yoshikawa A; Kusunoki Y; Matsui K; Negoro S; Takifuji N; Nakagawa K; Hirashima T
    Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
    Massacesi C; Terrazzino S; Marcucci F; Rocchi MB; Lippe P; Bisonni R; Lombardo M; Pilone A; Mattioli R; Leon A
    Cancer; 2006 Mar; 106(5):1007-16. PubMed ID: 16456808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
    Tsai HL; Huang CW; Lin YW; Wang JH; Wu CC; Sung YC; Chen TL; Wang HM; Tang HC; Chen JB; Ke TW; Tsai CS; Huang HY; Wang JY
    Eur J Cancer; 2020 Oct; 138():19-29. PubMed ID: 32829105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms].
    Li H; Huang H; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Dec; 46(12):888-91. PubMed ID: 22333276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
    Gao J; Zhou J; Li Y; Lu M; Jia R; Shen L
    Med Oncol; 2013; 30(3):604. PubMed ID: 23686699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.
    Xu JM; Wang Y; Ge FJ; Lin L; Liu ZY; Sharma MR
    World J Gastroenterol; 2013 Jun; 19(24):3899-903. PubMed ID: 23840132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT).
    Phelip JM; Mineur L; De la Fouchardière C; Chatelut E; Quesada JL; Roblin X; Pezet D; Mendoza C; Buc E; Rivoire M
    Ann Surg Oncol; 2016 Jul; 23(7):2161-6. PubMed ID: 26739304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
    Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
    J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.
    Shulman K; Cohen I; Barnett-Griness O; Kuten A; Gruber SB; Lejbkowicz F; Rennert G
    Cancer; 2011 Jul; 117(14):3156-62. PubMed ID: 21287524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
    Kim KP; Kim HS; Sym SJ; Bae KS; Hong YS; Chang HM; Lee JL; Kang YK; Lee JS; Shin JG; Kim TW
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1609-17. PubMed ID: 23595344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.
    Burris HA; Infante JR; Anthony Greco F; Thompson DS; Barton JH; Bendell JC; Nambu Y; Watanabe N; Jones SF
    Cancer Chemother Pharmacol; 2016 May; 77(5):1079-86. PubMed ID: 27061418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer.
    Fujii H; Yamada Y; Watanabe D; Matsuhashi N; Takahashi T; Yoshida K; Suzuki A
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):123-129. PubMed ID: 30377777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
    Catimel G; Chabot GG; Guastalla JP; Dumortier A; Cote C; Engel C; Gouyette A; Mathieu-Boué A; Mahjoubi M; Clavel M
    Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.
    Palomaki GE; Bradley LA; Douglas MP; Kolor K; Dotson WD
    Genet Med; 2009 Jan; 11(1):21-34. PubMed ID: 19125129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer.
    Xu Q; Ding YY; Song LX; Xu JF
    Genet Mol Res; 2015 Jun; 14(2):7241-7. PubMed ID: 26125934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G].
    Valenzuela Jiménez B; González Sales M; Escudero Ortiz V; Martínez Navarro E; Pérez Ruixo C; Rebollo Liceaga J; González Manzano R; Pérez Ruixo JJ
    Farm Hosp; 2013; 37(2):111-27. PubMed ID: 23789755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.